Variant of TYR and Autoimmunity Susceptibility Loci in Generalized Vitiligo (original) (raw)

. Author manuscript; available in PMC: 2010 Nov 6.

Published in final edited form as: N Engl J Med. 2010 Apr 21;362(18):1686–1697. doi: 10.1056/NEJMoa0908547

Abstract

BACKGROUND

Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, which results in patchy depigmentation of skin and hair, and is associated with an elevated risk of other autoimmune diseases.

METHODS

To identify generalized vitiligo susceptibility loci, we conducted a genomewide association study. We genotyped 579,146 single-nucleotide polymorphisms (SNPs) in 1514 patients with generalized vitiligo who were of European-derived white (CEU) ancestry and compared the genotypes with publicly available control genotypes from 2813 CEU persons. We then tested 50 SNPs in two replication sets, one comprising 677 independent CEU patients and 1106 CEU controls and the other comprising 183 CEU simplex trios with generalized vitiligo and 332 CEU multiplex families.

RESULTS

We detected significant associations between generalized vitiligo and SNPs at several loci previously associated with other autoimmune diseases. These included genes encoding major-histocompatibility-complex class I molecules (P = 9.05×10−23) and class II molecules (P = 4.50×10−34), PTPN22 (P = 1.31×10−7), LPP (P = 1.01×10−11), IL2RA (P = 2.78×10−9), UBASH3A (P = 1.26×10−9), and C1QTNF6 (P = 2.21×10−16). We also detected associations between generalized vitiligo and SNPs in two additional immune-related loci, RERE (P = 7.07×10−15) and GZMB (P = 3.44×10−8), and in a locus containing TYR (P = 1.60×10−18), encoding tyrosinase.

CONCLUSIONS

We observed associations between generalized vitiligo and markers implicating multiple genes, some associated with other autoimmune diseases and one (TYR) that may mediate target-cell specificity and indicate a mutually exclusive relationship between susceptibility to vitiligo and susceptibility to melanoma.

GENERALIZED VITILIGO IS A DISEASE IN which patchy depigmentation of skin and hair results from autoimmune loss of melanocytes.1,2 It is a complex disorder involving multiple susceptibility genes and unknown environmental triggers. Genetic linkage and candidate-gene association studies have implicated several potentially contributory loci, though few have been consistently supported by the data.3 Patients with generalized vitiligo have elevated frequencies of other autoimmune diseases, including autoimmune thyroid disease, rheumatoid arthritis, psoriasis, adult-onset type 1 diabetes, pernicious anemia, systemic lupus erythematosus, and Addison's disease,4 suggesting that these diseases involve shared genetic components. To identify susceptibility loci for generalized vitiligo, we performed a genome-wide association study of patients with the disease who were of European-derived white (abbreviated as CEU) ancestry.

METHODS

STUDY SUBJECTS

The initial, genomewide association study included 1514 CEU patients from North America and the United Kingdom (see Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). All patients met strict clinical criteria for the diagnosis of generalized vitiligo.5 The single-nucleotide polymorphism (SNP) genotypes of the patients were compared with those of 2813 CEU controls (from data sets obtained from the National Institutes of Health Genotype and Phenotype database [dbGaP]). We also carried out analyses of two independent CEU replication sets: replication set 1 included 677 unrelated patients with generalized vitiligo and 1106 controls, and replication set 2 was a family-based cohort of 183 simplex trios and 332 multiplex families. We obtained written informed consent from all the study participants, and the study was approved by the institutional review board at each participating center. Additional protocol details are provided in the Supplementary Appendix.

GENOTYPING AND QUALITY CONTROL

DNA purification, genotyping, and quality-control procedures are described in the Supplementary Appendix. In the genomewide association study, we determined the genotypes of patients with vitiligo for approximately 610,000 markers by using the Illumina 610-Quad BeadChip. All mitochondrial markers and Y-chromosome markers were excluded, leaving 579,146 SNPs that were present in both patients and controls in the genomewide association data set. Genotype data were then subjected to extensive quality-control filtering. In the two replication studies, genotyping of the SNPs that showed genomewide significance (P<5×10−8) or near significance in the genomewide association study was performed with the use of the Sequenom MassArray iPLEX genotyping system. We also imputed genotypes for rs12206499, which is related to major-histocompatibility-complex (MHC) class I molecules and for technical reasons could not be genotyped, and genotyped several SNPs in the NLRP1 (NLR family, pyrin domain–containing 1 gene) region, which was previously shown to be associated with vitiligo (see the Supplementary Appendix).

STATISTICAL ANALYSIS

After quality-control filtering of the SNPs (see the Supplementary Appendix), exclusion of genetic outliers, and exclusion of data from subjects who could not be matched to an appropriate control or patient,6 a total of 520,460 SNPs in 1392 patients and 2629 controls remained. We compared allele frequencies of these SNPs between the patients and controls by using the unadjusted Cochran–Armitage trend test7 as well as an eigenvector-adjusted Cochran–Armitage trend test.8 Both yielded a genomic inflation factor of 1.048, indicating minimal residual population stratification; we corrected the test statistics accordingly.9 After quality-control filtering of data obtained from the replication sets, for replication set 1 we compared the allele frequencies for the 48 genotyped SNPs, as well as the imputed SNP rs12206499, in 647 patients and 1056 controls by using the unadjusted Cochran–Armitage trend test.7 In replication set 2, we tested for an association with generalized vitiligo by using the family-based association test,10 version 1.5.5 (see the Supplementary Appendix). In the replication and combined analyses, P values of less than 0.05 were considered to indicate statistical significance (as opposed to the P<5×10−8 criterion in the genomewide association analysis).

RESULTS

GENOMEWIDE ASSOCIATION ANALYSIS

We compared the frequencies of alleles of 520,460 autosomal and X-chromosomal SNPs in 1392 unrelated patients with generalized vitiligo and in 2629 controls. The quantile–quantile plot of the negative logarithms of genomewide P values (excluding 3411 SNPs in the MHC) largely fit the null distribution (predicting no significant difference in P values between the two groups) (Fig. 1), except at the “tail,” where the observed P values were smaller than those expected under the null hypothesis. The most significant results after all corrections, including correction for a genomic inflation factor of 1.048,9 are shown in Table 1. Eight chromosomal regions contained SNPs associated with generalized vitiligo at the genomewide significance level (P<5×10−8).11 Summary statistical results and genotype data can be obtained from dbGaP (accession number, phs000224.v1.p1).

Figure 1. Genomewide Association Results.

Figure 1

The genomewide distribution of –log10 P values from the unadjusted Cochran–Armitage trend test is shown across the chromosomes. Values are shown for 520,460 polymorphic SNPs that were of sufficient quality, after quality-control filtering, in 1392 unrelated CEU patients with generalized vitiligo and 2629 unrelated CEU controls, after genetic matching6 and correction for the inflation factor of 1.048. The dotted line indicates the genomewide significance threshold (P<5×10–8). The inset shows quantile–quantile plots of the observed versus expected –log10 P values from the unadjusted Cochran–Armitage trend test. The plot in red shows P values for all 520,460 SNPs, whereas the plot in blue shows P values for all 520,460 SNPs excluding the 3417 SNPs located across the extended major histocompatibility complex (MHC) (on chromosome 6, spanning 26.0 to 33.5 Mb). C1QTNF6 denotes the C1q and tumor necrosis factor–related protein 6 gene, HLA-A the MHC class I, HLA-A gene, HLA-DRB1 the MHC class II, DR beta 1 gene, IL2RA the interleukin-2–receptor alpha gene, LPP the LIM domain–containing preferred translocation partner in lipoma gene, PTPN22 the lymphoid-specific protein tyrosine phosphatase, nonreceptor type 22 gene, RERE the arginine–glutamic acid dipeptide (RE) repeats gene, TYR the tyrosinase gene, and UBASH3A the ubiquitin-associated and SH3 domain–containing A gene.

Table 1.

Loci Most Strongly Associated with Generalized Vitiligo, According to the Analysis.*

Locus Region† SNP Nucleotide Location Risk Allele Genomewide Association Study‡ Replication Set 1§ Replication Set 2 Combined Analysis∥
Risk-Allele Frequency EIGENSTRAT P Value PLINK P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) Pseudo R2
Patients Controls
Chromosome 1p36.23
RERE rs301819 8424373 A 0.485 0.417 1.65×10−8 8.85×10−9 1.32 (1.21–1.45) 5.37×10−7 1.42 (1.24–1.63) 0.06 1.17 (0.96–1.43) 4.88×10−9 1.32 (1.20–1.45)
RERE rs4908760 8448729 G 0.433 0.373 6.52×10−7 3.48×10−7 1.28 (1.17–1.41) 1.02×10−8 1.50 (1.30–1.72) 0.27 1.09 (0.89–1.33) 7.07×10−15 1.36 (1.26–1.48) 0.008
RERE rs11121194 8492493 C 0.435 0.375 9.35×10−6 3.00×10−7 1.28 (1.17–1.41) 4.76×10−8 1.47 (1.28–1.69) 0.26 1.09 (0.89–1.33) 1.33×10−14 1.36 (1.26–1.47)
Chromosome 1p13.2
PTPN22 rs2476601 114179091 A 0.134 0.095 6.79×10−9 9.82×10−9 1.54 (1.33–1.78) 0.59 1.07 (0.84–1.69) 2.18×10−3 1.45 (1.04–2.03) 1.31×10−7 1.39 (1.23–1.57) 0.004
Chromosome 3q28
LPP rs13076312 189571948 T 0.510 0.445 3.46×10−8 3.96×10−8 1.30 (1.19–1.43) 8.52×10−5 1.33 (1.15–1.53) 2.31×10−3 1.23 (1.01–1.50) 2.70×10−11 1.30 (1.20–1.41)
LPP rs1464510 189595248 T 0.508 0.439 5.91×10−9 6.45×10−9 1.32 (1.21–1.45) 2.39×10−4 1.31 (1.13–1.51) 1.99×10−3 1.26 (1.03–1.54) 1.01×10−11 1.31 (1.21–1.41) 0.007
LPP rs13091753 189597283 T 0.459 0.399 7.36×10−7 7.83×10−7 1.27 (1.16–1.39) 4.47×10−3 1.24 (1.07–1.41) 0.03 1.19 (0.98–1.46) 1.03×10−8 1.26 (1.16–1.36)
LPP rs1559810 189607048 T 0.458 0.398 6.52×10−7 7.37×10−7 1.27 (1.16–1.39) 3.87×10−3 1.24 (1.07–1.43) 0.03 1.17 (0.96–1.43) 9.90×10−9 1.26 (1.16–1.36)
Chromosome 6p21.3 **
HLA-G rs2975033 29930240 T 0.382 0.289 9.12×10−16 1.16×10−15 1.49 (1.36–1.64) 7.90×10−4 1.29 (1.11–1.49) 1.20×10−5 1.54 (1.23–1.92) 3.72×10−19 1.45 (1.34–1.57)
HLA-A rs2517715 30025418 G 0.423 0.336 1.47×10−12 1.66×10−12 1.41 (1.29–1.55) 5.35×10−4 1.29 (1.11–1.48) 6.68×10−4 1.36 (1.10–1.68) 3.64×10−16 1.39 (1.28–1.51)
HLA-A–HCG9 rs3903160 30040876 T 0.382 0.285 8.75×10−17 1.04×10−16 1.52 (1.38–1.67) 1.43×10−3 1.28 (1.10–1.48) 2.40×10−5 1.49 (1.19–1.85) 3.40×10−19 1.45 (1.34–1.57)
HLA-A–HCG9 rs6457110 30041860 A 0.487 0.397 9.51×10−13 9.36×10−13 1.41 (1.29–1.55) 5.48×10−5 1.34 (1.16–1.54) 3.27×10−4 1.39 (1.11–1.73) 5.25×10−18 1.41 (1.30–1.52)
HLA-A–HCG9 rs3893464 30043229 C 0.625 0.535 1.72×10−12 1.44×10−12 1.38 (1.20–1.59) 4.55×10−6 1.38 (1.20–1.59) 8.05×10−4 1.44 (1.44–1.81) 3.54×10−18 1.42 (1.31–1.54)
HLA-A–HCG9 rs12206499 30045106 G 0.395 0.288 6.15×10−20 1.24×10−19 1.58 (1.43–1.74) 1.47×10−5 1.34 (1.17–1.53) ND 0.014
HLA-A–HCG9 rs3823355 30050062 T 0.392 0.286 1.12×10−19 2.13×10−19 1.57 (1.43–1.73) 8.69×10−4 1.29 (1.11–1.50) 2.50×10−6 1.52 (1.21–1.91) 9.05×10−23 1.50(1.39–1.63)
HCG9 rs6904029 30051046 A 0.391 0.287 4.06×10−19 7.89×10−19 1.56 (1.42–1.72) 1.50×10−3 1.27 (1.10–1.47) 2.40×10−5 1.49 (1.18–1.87) 9.79×10−22 1.49 (1.37–1.61)
HCG9 rs3823375 30052137 C 0.418 0.324 1.48×10−15 2.15×10−15 1.48 (1.35–1.63) 3.72×10−3 1.24 (1.07–1.43) 1.73×10−4 1.39 (1.13–1.72) 1.26×10−17 1.42 (1.31–1.53)
HCG9–HLA-J rs4947244 30062343 G 0.367 0.273 5.34×10−16 7.62×10×16 1.51 (1.37–1.66) 6.86×10−3 1.23 (1.06–1.43) 6.45×10−5 1.49 (1.19–1.86) 1.96×10−17 1.43 (1.32–1.55)
HLA-J rs4959039 30065048 G 0.366 0.273 8.82×10−16 1.28×10−15 1.50 (1.36–1.66) 3.25×10−3 1.25 (1.08–1.46) 1.00×10−5 1.58 (1.26–1.97) 2.23×10−17 1.43 (1.32–1.55)
HLA-J rs9357092 30092231 A 0.369 0.273 1.28×10−16 1.72×10−16 1.52 (1.38–1.68) 3.92×10−3 1.25 (1.07–1.45) 3.20×10−5 1.53 (1.22–1.91) 3.14×10−18 1.44 (1.33–1.57)
ZNRD1 rs9366752 30132656 T 0.307 0.228 6.17×10−13 6.59×10−13 1.47 (1.33–1.63) 1.35×10−3 1.29 (1.10–1.51) 2.19×10−4 1.45 (1.15–1.83) 1.56×10−15 1.42 (1.30–1.55)
RNF39 rs4711209 30155382 A 0.368 0.272 1.67×10−16 2.28×10−16 1.52 (1.38–1.67) 4.53×10−3 1.24 (1.07–1.44) 9.20×10−5 1.47 (1.18–1.84) 5.29×10−18 1.44 (1.32–1.56)
RNF39–TRIM31 rs6909253 30163622 G 0.508 0.414 2.51×10−13 1.70×10−13 1.42 (1.30–1.56) 5.94×10−4 1.28 (1.11–1.50) 4.13×10−4 1.44 (1.17–1.78) 2.13×10−15 1.37 (1.27–1.48)
RNF39–TRIM31 rs9261394 30172541 A 0.512 0.417 1.26×10−13 6.99×10−14 1.43 (1.31–1.57) 1.05×10−3 1.27 (1.10–1.46) 8.76×10−4 1.41 (1.14–1.75) 2.20×10−15 1.37 (1.27–1.48)
C6orf10–BTNL2 rs7758128 32453261 A 0.062 0.026 3.85×10−15 7.21×10−15 2.48 (1.97–3.12) 1.50×10−3 1.79 (1.24–2.56) 5.00×10−7 3.66 (2.22–6.04) 3.29×10−16 2.19 (1.80–2.65)
BTNL2–HLA-DRA rs3806156 32481676 T 0.474 0.370 2.31×10−18 4.97×10−18 1.53 (1.39–1.68) 0.01 1.20 (1.04–1.38) 5.00×10−7 1.72 (1.38–2.13) 7.22×10−19 1.42 (1.32–1.54)
HLA-DRA–HLA-DRB5 rs2395185 32541145 T 0.414 0.331 6.74×10−13 1.04×10−12 1.42 (1.29–1.56) 0.10 1.13 (0.97−1.32) 1.13×10−3 1.33 (1.06–1.66) 2.11×10−13 1.35 (1.25–1.47)
HLA-DRB1–HLA-DQA1 rs2516049 32678378 G 0.410 0.319 7.04×10−15 1.07×10−14 1.47 (1.33–1.61) 0.02 1.19 (1.03–1.39) 4.71×10−4 1.40 (1.12–1.75) 3.24×10−16 1.40 (1.29–1.52)
HLA-DRB1–HLA-DQA1 rs532098 32686030 T 0.597 0.458 2.89×10−30 4.83×10−30 1.74 (1.59–1.92) 3.95×10−4 1.28 (1.11–1.46) 6.00×10−9 1.87 (1.49–2.36) 4.50×10−34 1.62 (1.50–1.75) 0.018
HLA-DQA1 rs34518860 32702081 A 0.170 0.107 2.07×10−15 2.10×10−15 1.72 (1.51–1.96) ND ND
Chromosome 10p15.1
IL2RA rs706779 6138830 A 0.607 0.535 4.61×10−10 1.14×10−9 1.35 (1.23–1.48) 0.27 1.08 (0.94–1.24) 8.30×10−5 1.32 (1.07–1.62) 2.78×10−9 1.27 (1.17–1.37) 0.004
IL2RA rs7090530 6150881 A 0.669 0.599 1.07×10−9 1.54×10−9 1.35 (1.23–1.49) 0.51 1.05 (0.91–1.21) 4.40×10−5 1.29 (1.05–1.58) 1.21×10−8 1.26 (1.17–1.37)
IL2RA–RBM17 rs12251307 6163501 C 0.913 0.871 1.40×10−8 1.10×10−8 1.59 (1.36–1.86) 0.22 0.87 (0.70–1.09) 0.06 1.19 (0.85–1.66) 8.10×10−6 1.33 (1.18–1.52)
RBM17 rs4750005 6209691 T 0.587 0.520 6.97×10−9 1.12×10−8 1.32 (1.20–1.45) 0.38 1.09 (0.90–1.30) 6.97×10−3 1.27 (0.97–1.66) 1.35×10−8 1.27 (1.17–1.37)
RBM17–PFKB3 rs3920615 6216786 A 0.615 0.544 1.11×10−9 2.11×10−9 1.34 (1.22–1.47) 0.71 1.03 (0.89–1.18) 0.17 1.06 (0.84–1.34) 9.32×10−9 1.26 (1.16–1.36)
RBM17–PFKB3 rs4747887 6217688 T 0.615 0.544 1.21×10−9 2.34×10−9 1.34 (1.22–1.47) 0.60 1.04 (0.90–1.20) 0.20 1.04 (0.83–1.31) 6.83×10−9 1.26 (1.17–1.36)
RBM17–PFKB3 rs4750012 6217800 C 0.615 0.544 1.27×10−9 2.42×10−9 1.34 (1.22–1.47) 0.70 1.03 (0.89–1.19) 0.29 1.01 (0.80–1.26) 9.25×10−9 1.26 (1.16–1.36)
RBM17–PFKB3 rs7099083 6218242 G 0.615 0.544 1.21×10−9 2.27×10−9 1.34 (1.22–1.47) 0.65 1.03 (0.90–1.19) 0.23 1.03 (0.82–1.29) 7.20×10−9 1.26 (1.17–1.36)
Chromosome 11q14.3
TYR rs10830236 88540464 C 0.721 0.669 1.09×10−6 1.15×10−6 1.29 (1.17–1.43) 6.05×10−3 1.25 (1.07–1.46) 0.77 1.04 (0.83–1.31) 1.18×10−8 1.28 (1.18–1.40)
TYR rs11018528 88570025 A 0.764 0.707 3.69×10−8 3.25×10−8 1.36 (1.22–1.51) 4.00×10−3 1.27 (1.08–1.50) 0.48 1.01 (0.81–1.26) 1.69×10−10 1.34 (1.23–1.47)
TYR rs10765198 88609422 T 0.771 0.715 5.36×10−8 5.78×10−8 1.36 (1.22–1.51) 1.23×10−3 1.31 (1.11–1.55) 0.36 1.04 (0.84–1.29) 6.37×10−11 1.35 (1.23–1.48)
TYR rs1847134 88644901 A 0.754 0.685 2.37×10−10 2.01×10−10 1.42 (1.28–1.57) 1.95×10−5 1.42 (1.21–1.66) 0.40 1.03 (0.82–1.30) 3.76×10−15 1.42 (1.30–1.56)
TYR rs1393350 88650694 G 0.807 0.733 3.70×10−13 3.24×10−13 1.54 (1.37–1.72) 4.37×10−6 1.51 (1.26–1.79) 0.12 1.16 (0.91–1.47) 1.60×10−18 1.53 (1.39–1.68) 0.011
TYR rs1806319 88677584 A 0.692 0.630 7.86×10−8 8.52×10−8 1.31 (1.19–1.45) 1.47×10−4 1.34 (1.15–1.56) 0.83 1.04 (0.83–1.30) 2.12×10−11 1.33 (1.22–1.44)
Chromosome 14q12
GZMB rs8192917 24172000 G 0.282 0.236 3.46×10−6 5.54×10−6 1.28 (1.15–1.42) 4.87×10−4 1.33 (1.13–1.55) 0.03 1.35 (1.09–1.67) 3.44×10−8 1.28 (1.17–1.39) 0.005
GZMB rs2273844 24173254 A 0.280 0.236 5.74×10−6 9.24×10−6 1.28 (1.15–1.42) 4.04×10−4 1.33 (1.14–1.56) 0.02 1.40 (1.13–1.75) 6.78×10−8 1.27 (1.17–1.39)
Chromosome 21q22.3
UBASH3A rs11203203 42709255 A 0.432 0.373 1.56×10−7 1.72×10−7 1.30 (1.18–1.42) 2.58×10−3 1.24 (1.08–1.43) 0.04 1.15 (0.93–1.43) 1.26×10−9 1.27 (1.18–1.38) 0.005
UBASH3A rs2839511 42721590 A 0.287 0.227 9.71×10−9 1.17×10−8 1.36 (1.23–1.51) 0.13 1.13 (0.96–1.32) 0.02 1.21 (0.95–1.53) 5.14×10−9 1.30 (1.19–1.42)
Chromosome 22q13.1
C1QTNF6 rs229527 35911431 T 0.490 0.419 4.06×10−9 4.36×10−9 1.33 (1.21–1.46) 6.26×10−9 1.54 (1.33–1.78) 2.88×10−3 1.15 (0.94–1.40) 2.21×10−16 1.38 (1.28–1.50) 0.009
C1QTNF6 rs5756546 35919751 T 0.271 0.219 6.35×10−7 4.34×10−7 1.33 (1.19–1.48) 1.37×10−5 1.44 (1.22–1.70) 0.49 1.12 (0.91–1.40) 1.93×10−11 1.35 (1.24–1.48)

MHC Loci

The most strongly associated SNPs were distributed across the MHC on chromosome 6p21.3 (Fig. 1), with 124 MHC SNPs exceeding the threshold for genomewide significance (P<5×10−8) and 689 MHC SNPs ranked among the 2000 SNPs with the highest genomewide significance. We found two major MHC association peaks (Fig. 2). One peak was in the class I gene region, between HLA-A (encoding the MHC class I,HLA-A molecule) and HCG9 (encoding the HLA complex group 9), characterized by three SNPs: rs12206499 (P = 1.24×10−19 for the association with generalized vitiligo; odds ratio for the presence of the risk allele in patients vs. controls, 1.58), rs3823355 (P = 2.13×10−19; odds ratio, 1.57), and rs6904029 (P = 7.89×10−19; odds ratio, 1.56). The second peak was in the class II gene region, between HLA-DRB1 (the MHC class II, DR beta 1 gene) and HLA-DQA1 (the MHC class II, DQ alpha 1 gene), characterized by rs532098 (P = 4.83×10−30; odds ratio, 1.74) and rs3806156 (P = 4.97×10−18; odds ratio, 1.53). The highest odds ratio in the genomewide association study was 2.48, for rs7758128 (P = 7.21×10−15). A third, lower peak was located at the proximal end of the MHC class I gene region (Fig. 2A).

Figure 2. Detailed Results from the Genomewide Association Study and the Linkage-Disequilibrium Plot across the Major Histocompatibility Complex (MHC) on Chromosome 6p21.3.

Figure 2

Panel A shows the distribution of –log10 P values from the unadjusted Cochran–Armitage trend test in the genomewide association analysis, corrected by the genomic inflation factor of 1.048, for the 3417 SNPs located across the extended MHC region (on chromosome 6, spanning 26.0 to 33.5 Mb). Panel B shows the plot of linkage disequilibrium (r2) for the 22 NPs in the MHC region that were highly associated with generalized vitiligo and that were included in the logistic-regression analysis. The plot gives the physical positions of the markers (according to build 36.1 from the National Center for Biotechnology Information). Darker boxes indicate stronger linkage disequilibrium (range of possible r2 values, 0.0 to 1.0). BTNL2 denotes the butyrophilin-like protein 2 gene, HCG9 the HLA complex group 9 gene, HLA-A the MHC class I, HLA-A gene, HLA-DQA1 the MHC class II, DQ alpha 1 gene, and HLA-DRB1 the MHC class II, DR beta 1 gene.

SNPs in the two major association peaks, one in the MHC class I region and one in the MHC class II region, corresponded with different linkage-disequilibrium blocks (Fig. 2, and Table 2 in the Supplementary Appendix). To determine whether these two peaks represent independent associations with generalized vitiligo, rather than secondary associations due to long-range linkage disequilibrium across the MHC, we applied logistic-regression analysis12 to the 22 MHC-region SNPs that showed the strongest association with generalized vitiligo in the genomewide association study (Table 3 in the Supplementary Appendix). We observed that the major peak in the MHC class I region, represented by SNP rs12206499, and the major peak in the MHC class II region, represented by rs532098, constitute independent association signals, with no apparent epistasis between them (P = 0.38), indicating that susceptibility to vitiligo that is attributable to the MHC involves more than one locus.

We analyzed data for 180 participants from 27 CEU Centre d'Etude du Polymorphisme Humain (CEPH) reference families for whom class I and class II HLA genotypes, as well as SNP genotypes,13,14 were available and for 203 participants from 78 families with generalized vitiligo for whom class II HLA and SNP genotypes were available.15 We found strong linkage disequilibrium between the risk allele (G) at rs12206499 and HLA-A*02 (r2 = 0.964 and linkage-disequilibrium coefficient [D′] = 1.0 in the CEPH reference families) and moderate linkage disequilibrium between the risk allele (T) at rs532098 and HLADRB1*04 (r2 = 0.43 and D′ = 1.0 in the CEPH reference families; r2 = 0.19 and D′ = 0.83 in the families with generalized vitiligo). These findings were consistent with previous reports of an association of generalized vitiligo with both the HLA-A*02 allele16 and the HLA-DRB1*04 allele.15

Non-MHC Loci

Outside the MHC region, SNPs in seven different chromosomal regions showed a significant association with generalized vitiligo (Table 1 and Fig. 1 in the Supplementary Appendix). Five of these regions contain genes previously shown to be associated with other autoimmune diseases; for each region, the same high-risk SNP alleles associated with vitiligo were also associated with other autoimmune diseases.

We found an association between generalized vitiligo and SNP rs2476601 (P = 9.82×10−9; odds ratio for the presence of the risk allele in patients vs. controls, 1.54), on chromosome 1p13.2. This SNP is located in PTPN22, which encodes the lymphoid-specific protein tyrosine phosphatase, nonreceptor type 22, involved in T-cell–receptor signaling. The implicated variant is associated with many autoimmune diseases, including generalized vitiligo, and specifies an amino acid substitution, R620W, thought to have a direct effect on autoimmune susceptibility (rather than a benign effect through linkage disequilibrium with the “causal” SNP).17

We also found an association between generalized vitiligo and 11 SNPs on chromosome 3q28. These SNPs span the LPP gene region (including the LPP gene, encoding the LIM domain–containing preferred translocation partner in lipoma). Of the 11 SNPs, rs1464510 (P = 6.45×10−9; odds ratio, 1.32) and rs13076312 (P = 3.96×10−8; odds ratio, 1.30) showed genomewide significance. We observed tight linkage disequilibrium among most of the 11 SNPs; no haplotype was more strongly associated with disease than any component SNP. SNPs in the LPP gene region have also been associated with celiac disease and rheumatoid arthritis18 the function of the LPP protein is unknown.

Generalized vitiligo was also associated with 25 SNPs in the region of IL2RA (encoding the interleukin-2–receptor alpha chain) on chromosome 10p15.1, 8 of which showed genomewide significance. Of these, rs706779 (P = 1.14×10−9; odds ratio, 1.35) and rs7090530 (P = 1.54×10−9; odds ratio, 1.35) had the strongest association. Variants of IL2RA have been shown to be associated with type 1 diabetes,19 Graves' disease,20 multiple sclerosis,21 rheumatoid arthritis,22 and systemic lupus erythematosus.23 Elevated serum interleukin-2-receptor levels, which indicate T-cell activation,24 occur in many autoimmune diseases, including generalized vitiligo.25

There was also an association between generalized vitiligo and nine SNPs in the region spanning UBASH3A (the ubiquitin-associated and SH3 domain–containing A gene) on chromosome 21q22.3; of these, rs2839511 showed genomewide significance (P = 1.17×10−8; odds ratio, 1.36). UBASH3A encodes a regulator of T-cell–receptor signaling and is associated with type 1 diabetes.26 Also associated with type 1 diabetes27.28 (as well as rheumatoid arthritis29) are variants of C1QTNF6 (the C1q and tumor necrosis factor–related protein 6 gene), located on chromosome 22q13.1. The SNP rs229527 at this locus showed an association with generalized vitiligo (P = 4.36×10−9; odds ratio, 1.33).

In addition, we observed an association between generalized vitiligo and two non-MHC regions that have not previously been reported to be associated with autoimmune disease. The first was the RERE gene region (encoding the arginine–glutamic acid dipeptide [RE] repeats protein, also known as atrophin-like protein 1) on chromosome 1p36.23, in which 40 SNPs were identified as having an association, 1 of which showed genome-wide significance (rs301819; P = 8.85×10−9; odds ratio, 1.32). The most strongly associated SNPs in the RERE region were in tight linkage disequilibrium; no haplotype showed a significantly stronger association than any component SNP. The RERE protein is a transcriptional corepressor30 that is highly expressed in lymphoid cells and is thought to regulate apoptosis.31

Perhaps the most interesting association that we found was between generalized vitiligo and a locus on chromosome 11q14.3, consisting of 37 SNPs spanning the TYR gene region. The major allele of each SNP was associated with vitiligo. Three of these SNPs showed genomewide significance; the strongest associations were with rs1847134 (P = 2.01×10−10; odds ratio, 1.42) and rs1393350 (P=3.24×10−13; odds ratio, 1.54). Haplotype analysis revealed a strong association with a block of six SNPs in tight linkage disequilibrium — rs1018528, rs10765198, rs1847134, rs1393350, rs1126809, and rs1806319 — although no haplotype had a significantly stronger association with generalized vitiligo than any component SNP. TYR encodes tyrosinase, a melanosomal enzyme that catalyzes the rate-limiting steps of melanin biosynthesis32 and constitutes a major autoantigen in generalized vitiligo.1,2

Finally, we detected a suggestive association signal at chromosome 14q12, involving 11 SNPs spanning the GZMB (the granzyme B gene) region, particularly intragenic SNPs rs8192917 (P=5.54× 10−6; odds ratio, 1.28) and rs2273844 (P=9.24× 10−6; odds ratio, 1.28). Granzyme B is a caspaselike serine protease that mediates two processes: immune-induced target-cell apoptosis mediated by cytotoxic T cells and natural killer cells33 and activation-induced cell death of effector type 2 helper T cells, which terminates the immune response.34

Independent Replication and Combined Analyses

We aimed to replicate the results of the genomewide association analysis in two replication sets of independently collected samples from CEU patients and controls (replication set 1) and CEU simplex trios and multiplex families (replication set 2) (Table 1 in the Supplementary Appendix). Specifically, we tested 50 SNPs in nine chromosomal regions that had the strongest associations with generalized vitiligo, as detected in the genomewide association analysis (Table 1). In one or both replication sets, the results for most of these SNPs, and all the corresponding genomic regions tested, replicated the associations observed in the genomewide association analysis. Furthermore, a combined meta-analysis of all three study sets (by means of a Cochran–Mantel–Haenszel test) provided strong evidence of an association of all of these loci with generalized vitiligo (Table 1).

In the MHC region, both replication analyses and the combined analyses supported strong association in both the distal class I region (rs3823355; in the combined analysis, P=9.05× 10−23; odds ratio, 1.50) and the HLA-DRB1_–_DQA1 class II region (rs532098; in the combined analysis, P=4.50×10−34; odds ratio, 1.62). SNPs in the proximal class I region were not tested in the replication studies.

Outside the MHC, associations in the LPP region of chromosome 3q28, the GZMB region of chromosome 14q12, the UBASH3A region of chromosome 21q22.3, and the C1QTNF6 region of chromosome 22q13.1 were observed in both replication sets; the combined analysis likewise provided strong support for the associations (for LPP rs1464510, P=1.01×10−11; odds ratio, 1.31; for GZMB rs8192917, P=3.44×10−8; odds ratio, 1.28; for UBASH3A rs11203203, P=1.26×10−9; odds ratio 1.27; and for C1QTNF6 rs229527, P=2.21×10−16; odds ratio, 1.38). For PTPN22 on chromosome 1p13.2 and the IL2RA region of chromosome 10p15.1, associations were replicated in the family-based set (replication set 2) but not in the case–control set (replication set 1). Conversely, in the RERE region of chromosome 1p36.23 and the TYR region of chromosome 11q14.3, associations were replicated in the case–control set but not in the family-based set (Table 1). Nevertheless, for all these loci, the combined analysis provided strong support for an overall association (RERE rs4908760, P=7.07×10−15; odds ratio, 1.36; PTPN22 rs2476601, P=1.31×10−7; odds ratio, 1.39; IL2RA rs706779, P=2.78×10−9; odds ratio, 1.27; and TYR rs1393350, P=1.60×10−18; odds ratio, 1.53).

Thus, the replication studies showed consistent support for an association of generalized vitiligo with SNPs within or near LPP, the HLA class I and HLA class II genes, GZMB, UBASH3A, and C1QTNF6 and less consistent, although significant, support for an association with SNPs within or near RERE, PTPN22, IL2RA, and TYR.

Tyrosinase is naturally presented by HLAA*0201 and is recognized by autologous cytotoxic T lymphocytes on HLA-A2–positive melanomas, which tend to show good response to immunotherapy. Presentation of TYR peptide by HLA-A*0201 may also mediate the loss of partial self-tolerance to tyrosinase.35 We therefore tested epistasis between HLA-A SNP rs12206499 and TYR SNP rs1393350 with logistic regression analysis, using SNP genotypes from the genomewide association study and replication set 1, thereby detecting evidence of significant epistasis between HLA-A and TYR (P=0.03).

DISCUSSION

We identified 10 independent susceptibility loci for generalized vitiligo. In general, these associations were observed in both the subgroup of patients with vitiligo only and the subgroup with vitiligo and concomitant autoimmune diseases (Table 4 in the Supplementary Appendix). PTPN22 (rs2476601) was the exception; the risk allele was significantly more prevalent among patients with generalized vitiligo and other autoimmune diseases. In the MHC region, we detected two major association signals, one in the class I gene region, between HLA-A and HCG9, and the other in the class II gene region, between HLA-DRB1 and HLA-DQA1 (Fig. 2). This finding is consistent with previous reports of an association of vitiligo with the HLA-A*02 allele16 and the HLA-DRB1*04 allele.15 Indeed, the near-perfect linkage disequilibrium between HLA-A*02 and the risk variant at rs12206499 suggests that HLA-A*02 may be the etiologic variant at this locus that confers susceptibility to vitiligo.

Outside the MHC, we identified signals of an association with generalized vitiligo within or near the RERE, PTPN22, LPP, IL2RA, TYR, GZMB, UBASH3A, and C1QTNF6 genes. PTPN22, LPP, IL2RA, UBASH3A, and C1QTNF6 are also associated with genetic susceptibility to other autoimmune diseases, several of which are epidemiologically associated with generalized vitiligo. These findings support the long-standing hypothesis that generalized vitiligo involves genetic susceptibility loci shared with other autoimmune diseases.3 Most of these genes encode immune-system proteins involved in biologic pathways that probably influence the development of autoimmunity.

In contrast, TYR encodes tyrosinase, which is not a component of the immune system. Rather, it is an enzyme of the melanocyte that catalyzes the rate-limiting steps of melanin biosynthesis.32 It is also a major autoantigen in generalized vitiligo.1,2 Generalized vitiligo is thus genetically analogous to type 1 diabetes, in which variation in the INS gene, encoding insulin (an important autoantigen in diabetes), contributes to disease susceptibility. Vitiligo is associated with the major alleles of SNPs in the TYR region, particularly rs1393350 (in the combined analysis, P=1.60×10−18; odds ratio, 1.53) and the nearby nonsynonymous (R402Q) SNP rs1126809 (Table 5 in the Supplementary Appendix), with which rs1393350 is in tight linkage disequilibrium (Table 6 in the Supplementary Appendix). The minor alleles of both these SNPs are associated with susceptibility to malignant melanoma,36,37 suggesting that susceptibility to _TYR_-related generalized vitiligo and susceptibility to _TYR_-related malignant melanoma are mediated by different or perhaps even inverse biologic mechanisms. The 402Q variant of the TYR protein (the variant associated with melanoma) is thermosensitive38 and at 37°C tends to be misfolded, aberrantly glycosylated, retained in the endoplasmic reticulum, and subject to proteosomal degradation,39 resulting in steady-state 402Q tyrosinase activity that is only 25% of that of the major 402R polypeptide (which is associated with susceptibility to generalized vitiligo).38 Correct glycosylation of tyrosinase augments the generation of an MHC class I–restricted tyrosinase epitope that is presented by HLA-A*0201,40 the predominant HLA-A*02 allele, and indeed, we detected significant epistasis between HLA-A SNP rs12206499 and TYR SNP rs1393350 (P=0.03).

Thus, 402R tyrosinase not only is expressed at higher levels than the 402Q variant but also may be more efficiently presented to the immune system by HLA-A*02. It is therefore plausible that the 402R variant makes a greater contribution than the 402Q variant to immune surveillance against neoplastic melanocytes and susceptibility to vitiligo. On the other hand, in persons carrying one or two copies of the 402Q variant, immune surveillance may fail to detect neoplastic melanocytes, owing to the reduced expression, and thus the reduced immune presentation, of tyrosinase.

Generally, there is limited correspondence between the associations shown in the present study and genetic linkage and candidate-gene association signals reported previously for generalized vitiligo,3 though a detailed analysis supported an association with NLRP1 in multiplex families and specific subgroups of patients (see the Supplementary Appendix). Moreover, none of the significant associations reported in this study correspond to the principal up-regulated or down-regulated transcripts identified with the use of gene-expression profiling of melanocytes from patients with generalized vitiligo.41 Although the implicated loci that we have described here together account for only approximately 7.4% of the total genetic risk for generalized vitiligo, they provide insights into disease pathogenesis and implicate potential targets for therapeutic intervention.

Supplementary Material

Supp

Acknowledgments

Supported by grants (AR45584 and AR056292) from the National Institutes of Health and a grant from the Anna and John Sie Foundation.

We thank Deborah Herbstman, Amanda Tran, the University of Colorado Microarray Core, the Genotyping Core in the Division of Human Genetics at Washington University School of Medicine in St. Louis, and the membership of Vitiligo Support International, the Vitiligo Society, the National Vitiligo Foundation, the American Vitiligo Research Foundation, and Associazione Ricerca Informazione per la Vitiligine for their participation.

Footnotes

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp